B cell activating factor in juvenile onset systemic lupus erythematosus, looking beyond the B cell

Abstract

Introduction Increased B cell activating factor (BAFF) in the serum of juvenile-onset systemic lupus erythematosus (JSLE) patients is thought to be key to the survival of autoreactive B cells. BAFF signals through three receptors, BAFF-R, BCMA and TACI, activating the NFB pathway. Belimumab is a human monoclonal antibody against BAFF that has recently become the first drug licensed for the treatment of SLE in 50 years. In order to investigate the potential effect of BAFF inhibition on the wider immune system, receptor expression was investigated in another SLE pathogenic cell, the T lymphocyte.

Cite this paper

@inproceedings{Richards2014BCA, title={B cell activating factor in juvenile onset systemic lupus erythematosus, looking beyond the B cell}, author={Ella Richards and Angela Midgely and Thomas Morgan and Michael W Beresford}, year={2014} }